Download PDF
Semin Respir Crit Care Med 2022; 43(04): 570-582
DOI: 10.1055/s-0042-1748186
Review Article

Nonmalignant Pleural Effusions

José M. Porcel
1   Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, University of Lleida, Lleida, Spain
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Although the potential causes of nonmalignant pleural effusions are many, the management of a few, including complicated pleural infections and refractory heart failure and hepatic hydrothoraces, can be challenging and requires the assistance of interventional pulmonologists. A pragmatic approach to complicated parapneumonic effusions or empyemas is the insertion of a small-bore chest tube (e.g., 14–16 Fr) through which fibrinolytics (e.g., urokinase and alteplase) and DNase are administered in combination. Therapeutic thoracenteses are usually reserved for small to moderate effusions that are expected to be completely aspirated at a single time, whereas video-assisted thoracic surgery should be considered after failure of intrapleural enzyme therapy. Refractory cardiac and liver-induced pleural effusions portend a poor prognosis. In cases of heart failure–related effusions, therapeutic thoracentesis is the first-line palliative therapy. However, if it is frequently needed, an indwelling pleural catheter (IPC) is recommended. In patients with hepatic hydrothorax, repeated therapeutic thoracenteses are commonly performed while a multidisciplinary decision on the most appropriate definitive management is taken. The percutaneous creation of a portosystemic shunt may be used as a bridge to liver transplantation or as a potential definitive therapy in nontransplant candidates. In general, an IPC should be avoided because of the high risk of complications, particularly infections, that may jeopardize candidacy for liver transplantation. Even so, in noncandidates for liver transplant or surgical correction of diaphragmatic defects, IPC is a therapeutic option as valid as serial thoracenteses.

Keywords

indwelling pleural catheter - therapeutic thoracentesis - pleurodesis - empyema - heart failure - hepatic hydrothorax - chest tube


Publication History

Article published online:
14 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bodtger U, Hallifax RJ. Epidemiology: why is pleural disease becoming more common?. In: Maskell NA, Laursen CB, Lee YCG. et al, eds. Pleural Disease (ERS Monograph). Sheffield, European Respiratory Society; 2020: 1-12 [https://doi.org/10.1183/2312508X.10022819]
    Google Scholar
  • 2 Mummadi SR, Stoller JK, Lopez R, Kailasam K, Gillespie CT, Hahn PY. Epidemiology of adult pleural disease in the United States. Chest 2021; 160 (04) 1534-1551
    CrossrefPubMedGoogle Scholar
  • 3 Walker SP, Morley AJ, Stadon L. et al. Nonmalignant pleural effusions: a prospective study of 356 consecutive unselected patients. Chest 2017; 151 (05) 1099-1105
    CrossrefPubMedGoogle Scholar
  • 4 Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol 2014; 50 (05) 161-165
    CrossrefPubMedGoogle Scholar
  • 5 Tian P, Qiu R, Wang M. et al. Prevalence, causes, and health care burden of pleural effusions among hospitalized adults in China. JAMA Netw Open 2021; 4 (08) e2120306
    CrossrefPubMedGoogle Scholar
  • 6 Cargill TN, Hassan M, Corcoran JP. et al. A systematic review of comorbidities and outcomes of adult patients with pleural infection. Eur Respir J 2019; 54 (03) 1900541
    CrossrefPubMedGoogle Scholar
  • 7 Porcel JM. PILOTing towards a RAPID predictor of mortality for infectious pleural effusions. Eur Respir J 2020; 56 (05) 2002425
    CrossrefPubMedGoogle Scholar
  • 8 Bobbio A, Bouam S, Frenkiel J. et al. Epidemiology and prognostic factors of pleural empyema. Thorax 2021; 76 (11) 1117-1123
    CrossrefPubMedGoogle Scholar
  • 9 Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest 2014; 145 (04) 848-855
    CrossrefPubMedGoogle Scholar
  • 10 Corcoran JP, Psallidas I, Gerry S. et al. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. Eur Respir J 2020; 56 (05) 2000130
    CrossrefPubMedGoogle Scholar
  • 11 Lehtomäki A, Nevalainen R, Ukkonen M, Nieminen J, Laurikka J, Khan J. Trends in the incidence, etiology, treatment, and outcomes of pleural infections in adults over a decade in a Finnish University Hospital. Scand J Surg 2020; 109 (02) 127-132
    CrossrefPubMedGoogle Scholar
  • 12 Falguera M, Carratalà J, Bielsa S. et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J 2011; 38 (05) 1173-1179
    CrossrefPubMedGoogle Scholar
  • 13 Porcel JM. Minimally invasive treatment of complicated parapneumonic effusions and empyemas in adults. Clin Respir J 2018; 12 (04) 1361-1366
    CrossrefPubMedGoogle Scholar
  • 14 Ferreiro L, Porcel JM, Bielsa S, Toubes ME, Álvarez-Dobaño JM, Valdés L. Management of pleural infections. Expert Rev Respir Med 2018; 12 (06) 521-535
    CrossrefPubMedGoogle Scholar
  • 15 Hassan M, Patel S, Sadaka AS, Bedawi EO, Corcoran JP, Porcel JM. Recent insights into the management of pleural infection. Int J Gen Med 2021; 14: 3415-3429
    CrossrefPubMedGoogle Scholar
  • 16 Hassan M, Cargill T, Harriss E. et al. The microbiology of pleural infection in adults: a systematic review. Eur Respir J 2019; 54 (03) 1900542
    CrossrefPubMedGoogle Scholar
  • 17 Porcel JM, Ferreiro L, Rumi L. et al. Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial. Pleura Peritoneum 2020; 5 (01) 20190027
    CrossrefPubMedGoogle Scholar
  • 18 Letheulle J, Tattevin P, Saunders L. et al. Iterative thoracentesis as first-line treatment of complicated parapneumonic effusion. PLoS One 2014; 9 (01) e84788
    CrossrefPubMedGoogle Scholar
  • 19 Luque Paz D, Bayeh B, Chauvin P. et al. Intrapleural use of urokinase and DNase in pleural infections managed with repeated thoracentesis: a comparative cohort study. PLoS One 2021; 16 (09) e0257339
    CrossrefPubMedGoogle Scholar
  • 20 Porcel JM, Azzopardi M, Koegelenberg CF, Maldonado F, Rahman NM, Lee YC. The diagnosis of pleural effusions. Expert Rev Respir Med 2015; 9 (06) 801-815
    CrossrefPubMedGoogle Scholar
  • 21 Porcel JM. Distinguishing complicated from uncomplicated parapneumonic effusions. Curr Opin Pulm Med 2015; 21 (04) 346-351
    CrossrefPubMedGoogle Scholar
  • 22 Meyer CN, Armbruster K, Kemp M, Thomsen TR, Dessau RB. Danish Pleural Empyema Group. Pleural infection: a retrospective study of clinical outcome and the correlation to known etiology, co-morbidity and treatment factors. BMC Pulm Med 2018; 18 (01) 160
    CrossrefPubMedGoogle Scholar
  • 23 Porcel JM, Valencia H, Bielsa S. Factors influencing pleural drainage in parapneumonic effusions. Rev Clin Esp (Barc) 2016; 216 (07) 361-366
    CrossrefPubMedGoogle Scholar
  • 24 Chang SY, Chen YC, Tsai CL. et al. Sonographic septation: a useful diagnostic predictor of complicated parapneumonic effusion. J Investig Med 2021; 69 (08) 1447-1452
    CrossrefPubMedGoogle Scholar
  • 25 Porcel JM, Pardina M, Alemán C, Pallisa E, Light RW, Bielsa S. Computed tomography scoring system for discriminating between parapneumonic effusions eventually drained and those cured only with antibiotics. Respirology 2017; 22 (06) 1199-1204
    CrossrefPubMedGoogle Scholar
  • 26 Gilbert CR, Jackson AS, Wilshire CL. et al. Cumulative radiation dose incurred during the management of complex pleural space infection. BMC Pulm Med 2021; 21 (01) 132
    CrossrefPubMedGoogle Scholar
  • 27 Porcel JM. Chest tube drainage of the pleural space: a concise review for pulmonologists. Tuberc Respir Dis (Seoul) 2018; 81 (02) 106-115
    CrossrefPubMedGoogle Scholar
  • 28 Rahman NM, Maskell NA, Davies CW. et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest 2010; 137 (03) 536-543
    CrossrefPubMedGoogle Scholar
  • 29 Maskell NA, Davies CW, Nunn AJ. et al; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352 (09) 865-874
    CrossrefPubMedGoogle Scholar
  • 30 Kanellakis NI, Wrightson JM, Hallifax R. et al. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients. BMJ Open Respir Res 2019; 6 (01) e000440
    CrossrefPubMedGoogle Scholar
  • 31 Livingston MH, Mahant S, Connolly B. et al. Effectiveness of intrapleural tissue plasminogen activator and dornase alfa vs tissue plasminogen activator alone in children with pleural empyema: a randomized clinical trial. JAMA Pediatr 2020; 174 (04) 332-340
    CrossrefPubMedGoogle Scholar
  • 32 Rahman NM, Maskell NA, West A. et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (06) 518-526
    CrossrefPubMedGoogle Scholar
  • 33 Porcel JM. Dual intracavitary therapy for pleural infections: leaving reluctance behind. Eur Respir J 2019; 54 (02) 1901001
    CrossrefPubMedGoogle Scholar
  • 34 Altmann ES, Crossingham I, Wilson S, Davies HR. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2019; 2019 (10) CD002312
    PubMedGoogle Scholar
  • 35 Alemán C, Porcel JM, Alegre J. et al. Intrapleural fibrinolysis with Urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung 2015; 193 (06) 993-1000
    CrossrefPubMedGoogle Scholar
  • 36 Bédat B, Plojoux J, Noel J. et al. Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. ERJ Open Res 2019; 5 (03) 00084-02019
    CrossrefPubMedGoogle Scholar
  • 37 Luengo-Fernandez R, Penz E, Dobson M. et al. Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial. Eur Respir J 2019; 54 (02) 1801550
    CrossrefPubMedGoogle Scholar
  • 38 Chaddha U, Agrawal A, Feller-Kopman D. et al. Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. Lancet Respir Med 2021; 9 (09) 1050-1064
    CrossrefPubMedGoogle Scholar
  • 39 Popowicz N, Bintcliffe O, De Fonseka D. et al. Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for pleural infection therapy project. Ann Am Thorac Soc 2017; 14 (06) 929-936
    CrossrefPubMedGoogle Scholar
  • 40 Jiang C, Xie M, Cervellione K, Thurm C. Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study. BMC Res Notes 2020; 13 (01) 368
    CrossrefPubMedGoogle Scholar
  • 41 McClune JR, Wilshire CL, Gorden JA. et al. Safety and efficacy of intrapleural tissue plasminogen activator and DNAse during extended use in complicated pleural space infections. Can Respir J 2016; 2016: 9796768
    CrossrefPubMedGoogle Scholar
  • 42 Beckert L, Brockway B, Simpson G. et al. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight 2019; 5 (10) e127470
    CrossrefPubMedGoogle Scholar
  • 43 Arnold DT, Hamilton FW, Elvers KT. et al. Pleural fluid suPAR levels predict the need for invasive management in parapneumonic effusions. Am J Respir Crit Care Med 2020; 201 (12) 1545-1553
    CrossrefPubMedGoogle Scholar
  • 44 Khemasuwan D, Sorensen J, Griffin DC. Predictive variables for failure in administration of intrapleural tissue plasminogen activator/deoxyribonuclease in patients with complicated parapneumonic effusions/empyema. Chest 2018; 154 (03) 550-556
    CrossrefPubMedGoogle Scholar
  • 45 Hooper CE, Edey AJ, Wallis A. et al. Pleural irrigation trial (PIT): a randomised controlled trial of pleural irrigation with normal saline versus standard care in patients with pleural infection. Eur Respir J 2015; 46 (02) 456-463
    CrossrefPubMedGoogle Scholar
  • 46 Porcel JM, Valencia H, Bielsa S. Manual Intrapleural saline flushing plus urokinase: a potentially useful therapy for complicated parapneumonic effusions and empyemas. Lung 2017; 195 (01) 135-138
    CrossrefPubMedGoogle Scholar
  • 47 Psallidas I, Kanellakis NI, Bhatnagar R. et al. A pilot feasibility study in establishing the role of ultrasound-guided pleural biopsies in pleural infection (the AUDIO study). Chest 2018; 154 (04) 766-772
    CrossrefPubMedGoogle Scholar
  • 48 Mondoni M, Saderi L, Trogu F. et al. Medical thoracoscopy treatment for pleural infections: a systematic review and meta-analysis. BMC Pulm Med 2021; 21 (01) 127
    CrossrefPubMedGoogle Scholar
  • 49 Kheir F, Thakore S, Mehta H. et al; Randomized Controlled Clinical Trial. Intrapleural fibrinolytic therapy versus early medical thoracoscopy for treatment of pleural infection. Ann Am Thorac Soc 2020; 17 (08) 958-964
    CrossrefPubMedGoogle Scholar
  • 50 Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Database Syst Rev 2017; 3 (03) CD010651
    PubMedGoogle Scholar
  • 51 Pan H, He J, Shen J, Jiang L, Liang W, He J. A meta-analysis of video-assisted thoracoscopic decortication versus open thoracotomy decortication for patients with empyema. J Thorac Dis 2017; 9 (07) 2006-2014
    CrossrefPubMedGoogle Scholar
  • 52 Shen KR, Bribriesco A, Crabtree T. et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017; 153 (06) e129-e146
    CrossrefPubMedGoogle Scholar
  • 53 Patella M, Minerva EM, Porcellini I, Cianfarani A, Tessitore A, Cafarotti S. Tracking the outcomes of surgical treatment of Stage 2 and 3 empyema: introduction and consolidation of minimally invasive approach. ANZ J Surg 2021; 91 (10) 2182-2187
    CrossrefPubMedGoogle Scholar
  • 54 Jagelavicius Z, Jovaisas V, Mataciunas M, Samalavicius NE, Janilionis R. Preoperative predictors of conversion in thoracoscopic surgery for pleural empyema. Eur J Cardiothorac Surg 2017; 52 (01) 70-75
    CrossrefPubMedGoogle Scholar
  • 55 Sokouti M, Sadeghi R, Pashazadeh S. et al. Treating empyema thoracis using video-assisted thoracoscopic surgery and open decortication procedures: a systematic review and meta-analysis by meta-mums tool. Arch Med Sci 2019; 15 (04) 912-935
    CrossrefPubMedGoogle Scholar
  • 56 Lardinois D, Gock M, Pezzetta E. et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video-assisted thoracoscopic surgery for empyema. Ann Thorac Surg 2005; 79 (06) 1851-1856
    CrossrefPubMedGoogle Scholar
  • 57 Stefani A, Aramini B, della Casa G. et al. Preoperative predictors of successful surgical treatment in the management of parapneumonic empyema. Ann Thorac Surg 2013; 96 (05) 1812-1819
    CrossrefPubMedGoogle Scholar
  • 58 Chung JH, Lee SH, Kim KT, Jung JS, Son HS, Sun K. Optimal timing of thoracoscopic drainage and decortication for empyema. Ann Thorac Surg 2014; 97 (01) 224-229
    CrossrefPubMedGoogle Scholar
  • 59 Wilshire CL, Jackson AS, Horslen LC. et al. Clinical evolution of practice patterns in the management of pleural space infections: a community-based healthcare network review. Ann Am Thorac Soc 2021; 18 (09) 1592-1594
    CrossrefPubMedGoogle Scholar
  • 60 Davies HE, Rahman NM, Parker RJ, Davies RJ. Use of indwelling pleural catheters for chronic pleural infection. Chest 2008; 133 (02) 546-549
    CrossrefPubMedGoogle Scholar
  • 61 Bhatnagar R, Reid ED, Corcoran JP. et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax 2014; 69 (10) 959-961
    CrossrefPubMedGoogle Scholar
  • 62 Li P, Hosseini S, Zhang T, Amjadi K. Clinical predictors of successful and earlier removal of indwelling pleural catheters in benign pleural effusions. Respiration 2019; 98 (03) 239-245
    CrossrefPubMedGoogle Scholar
  • 63 Majid A, de Lima A, Parikh M, Chee A, Fernandez-Bussy S, Kheir F. Tunneled pleural catheters for patients with chronic pleural infection and nonexpandable lung. J Bronchology Interv Pulmonol 2019; 26 (02) 132-136
    CrossrefPubMedGoogle Scholar
  • 64 Llorens P, Javaloyes P, Masip J. et al; Grupo ICA-SEMES. Prognostic value of chest radiographs in patients with acute heart failure: the Radiology in Acute Heart Failure (RAD-ICA) study. Emergencias 2019; 31 (05) 318-326
    PubMedGoogle Scholar
  • 65 Morales-Rull JL, Bielsa S, Conde-Martel A. et al; RICA Investigators Group. Pleural effusions in acute decompensated heart failure: prevalence and prognostic implications. Eur J Intern Med 2018; 52: 49-53
    CrossrefPubMedGoogle Scholar
  • 66 Pan D, Pellicori P, Dobbs K. et al. Prognostic value of the chest X-ray in patients hospitalised for heart failure. Clin Res Cardiol 2021; 110 (11) 1743-1756
    CrossrefPubMedGoogle Scholar
  • 67 Lindner M, Thomas R, Claggett B. et al. Quantification of pleural effusions on thoracic ultrasound in acute heart failure. Eur Heart J Acute Cardiovasc Care 2020; 9 (05) 513-521
    CrossrefPubMedGoogle Scholar
  • 68 Porcel JM. Pleural effusions from congestive heart failure. Semin Respir Crit Care Med 2010; 31 (06) 689-697
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Gundersen GH, Norekvål TM, Graven T. et al. Patient-reported outcomes and associations with pleural effusion in outpatients with heart failure: an observational cohort study. BMJ Open 2017; 7 (03) e013734
    CrossrefPubMedGoogle Scholar
  • 70 Löfström U, Hage C, Savarese G. et al. Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. ESC Heart Fail 2019; 6 (04) 830-839
    CrossrefPubMedGoogle Scholar
  • 71 Shetty S, Malik AH, Aronow WS, Alvarez P, Briasoulis A. Outcomes of thoracentesis for acute heart failure in hospitals. Am J Cardiol 2020; 125 (12) 1863-1869
    CrossrefPubMedGoogle Scholar
  • 72 Yaku H, Seko Y, Kato T, Morimoto T, Kimura T. Prognostic implications of residual pleural effusions at discharge in patients with acute decompensated heart failure. Eur J Intern Med 2021; 85: 133-135
    CrossrefPubMedGoogle Scholar
  • 73 Kataoka H. Pericardial and pleural effusions in decompensated chronic heart failure. Am Heart J 2000; 139 (05) 918-923
    CrossrefPubMedGoogle Scholar
  • 74 Porcel JM. PLEASE, take a deep breath. Eur Respir J 2020; 55 (05) 2000501
    CrossrefPubMedGoogle Scholar
  • 75 Fong C, Tan CWC, Tan DKY, See KC. Safety of thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy: a systematic review and meta-analysis. Chest 2021; 160 (05) 1875-1889
    CrossrefPubMedGoogle Scholar
  • 76 Lazarevic A, Dobric M, Goronja B. et al. Lung ultrasound-guided therapeutic thoracentesis in refractory congestive heart failure. Acta Cardiol 2020; 75 (05) 398-405
    CrossrefPubMedGoogle Scholar
  • 77 Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117 (05) 1404-1409
    CrossrefPubMedGoogle Scholar
  • 78 Freeman RK, Ascioti AJ, Dake M, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion. Ann Thorac Surg 2014; 97 (06) 1872-1876 discussion 1876–1877
    CrossrefPubMedGoogle Scholar
  • 79 Bramley K, DeBiasi E, Puchalski J. Indwelling pleural catheter placement for nonmalignant pleural effusions. Semin Respir Crit Care Med 2018; 39 (06) 713-719
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Patil M, Dhillon SS, Attwood K, Saoud M, Alraiyes AH, Harris K. Management of benign pleural effusions using indwelling pleural catheters: a systematic review and meta-analysis. Chest 2017; 151 (03) 626-635
    CrossrefPubMedGoogle Scholar
  • 81 Majid A, Kheir F, Fashjian M. et al. Tunneled pleural catheter placement with and without talc poudrage for treatment of pleural effusions due to congestive heart failure. Ann Am Thorac Soc 2016; 13 (02) 212-216
    CrossrefPubMedGoogle Scholar
  • 82 Porcel JM, Torres M, Pardina M, Civit C, Salud A, Bielsa S. Predictors of indwelling pleural catheter removal and infection: a single-center experience with 336 procedures. J Bronchology Interv Pulmonol 2020; 27 (02) 86-94
    CrossrefPubMedGoogle Scholar
  • 83 Walker SP, Bintcliffe O, Keenan E. et al. Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions. Eur Respir J 2022; 59 (02) 2101362
    CrossrefPubMedGoogle Scholar
  • 84 Gilbert CR, Porcel JM. Management of recurrent transudative effusions: can we REDUCE unnecessary interventions?. Eur Respir J. 2022; 59 (02) 2101942
    CrossrefPubMedGoogle Scholar
  • 85 Banini BA, Alwatari Y, Stovall M. et al. Multidisciplinary management of hepatic hydrothorax in 2020: an evidence-based review and guidance. Hepatology 2020; 72 (05) 1851-1863
    CrossrefPubMedGoogle Scholar
  • 86 Deleuran T, Watson H, Vilstrup H, Jepsen P. Risk factors for hepatic hydrothorax in cirrhosis patients with ascites - a clinical cohort study. Dig Dis Sci 2022; 67: 3395-3401
    CrossrefPubMedGoogle Scholar
  • 87 Hung TH, Tseng CW, Tsai CC, Tsai CC, Tseng KC, Hsieh YH. The long-term outcomes of cirrhotic patients with pleural effusion. Saudi J Gastroenterol 2018; 24 (01) 46-51
    CrossrefPubMedGoogle Scholar
  • 88 O'Leary JG, Rajender Reddy K. et al. Increased risk of ACLF and inpatient mortality in hospitalized patients with cirrhosis and hepatic hydrothorax. Dig Dis Sci 2021; 66 (10) 3612-3618
    CrossrefPubMedGoogle Scholar
  • 89 Matei D, Craciun R, Crisan D. et al. Hepatic hydrothorax - an independent decompensating event associated with long-term mortality in patients with cirrhosis. J Clin Med 2021; 10 (16) 3688
    CrossrefPubMedGoogle Scholar
  • 90 Rendón-Ramírez EJ, González-Villarreal M, Muñoz-Espinoza LE. et al. Pleural effusions identified by point-of-care ultrasound predict poor outcomes in decompensated cirrhosis. Ultrasound Med Biol 2021; 47 (11) 3283-3290
    CrossrefPubMedGoogle Scholar
  • 91 Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014; 20 (04) 352-357
    CrossrefPubMedGoogle Scholar
  • 92 Aithal GP, Palaniyappan N, China L. et al. Guidelines on the management of ascites in cirrhosis. Gut 2021; 70 (01) 9-29
    CrossrefPubMedGoogle Scholar
  • 93 Porcel JM, Mas E, Reñé JM, Bielsa S. Hidrotórax de causa hepática: análisis de 77 pacientes. [Hepatic hydrothorax: report of a series of 77 patients] Med Clin (Barc) 2013; 141 (11) 484-486
    CrossrefPubMedGoogle Scholar
  • 94 Gilbert CR, Shojaee S, Maldonado F. et al. How I do it: pleural interventions in the management of hepatic hydrothorax. Chest 2022; 161 (01) 276-283
    CrossrefPubMedGoogle Scholar
  • 95 Sagar AES, Landaeta MF, Adrianza AM. et al. Complications following symptom-limited thoracentesis using suction. Eur Respir J 2020; 56 (05) 1902356
    CrossrefPubMedGoogle Scholar
  • 96 Shojaee S, Khalid M, Kallingal G, Kang L, Rahman N. Repeat thoracentesis in hepatic hydrothorax and non-hepatic hydrothorax effusions: a case-control study. Respiration 2018; 96 (04) 330-337
    CrossrefPubMedGoogle Scholar
  • 97 Liu LU, Haddadin HA, Bodian CA. et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004; 126 (01) 142-148
    CrossrefPubMedGoogle Scholar
  • 98 Orman ES, Lok AS. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3 (04) 582-586
    CrossrefPubMedGoogle Scholar
  • 99 Hung TH, Tseng CW, Tsai CC, Hsieh YH, Tseng KC, Tsai CC. Mortality following catheter drainage versus thoracentesis in cirrhotic patients with pleural effusion. Dig Dis Sci 2017; 62 (04) 1080-1085
    CrossrefPubMedGoogle Scholar
  • 100 Ridha A, Al-Abboodi Y, Fasullo M. The outcome of thoracentesis versus chest tube placement for hepatic hydrothorax in patients with cirrhosis: a nationwide analysis of the national inpatient sample. Gastroenterol Res Pract 2017; 2017: 5872068
    CrossrefPubMedGoogle Scholar
  • 101 Assouad J, Barthes FleP, Shaker W, Souilamas R, Riquet M. Recurrent pleural effusion complicating liver cirrhosis. Ann Thorac Surg 2003; 75 (03) 986-989
    CrossrefPubMedGoogle Scholar
  • 102 Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: a systematic review and cumulative meta-analysis. World J Hepatol 2015; 7 (13) 1797-1806
    CrossrefPubMedGoogle Scholar
  • 103 Jindal A, Mukund A, Kumar G, Sarin SK. Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis. Liver Int 2019; 39 (11) 2164-2173
    CrossrefPubMedGoogle Scholar
  • 104 Boike JR, Thornburg BG, Asrani SK. et al; Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. [Published online ahead of print, July 15, 2021]Clin Gastroenterol Hepatol 2021:S1542–3565(21)00749-7
    PubMedGoogle Scholar
  • 105 Hou F, Qi X, Guo X. Effectiveness and safety of pleurodesis for hepatic hydrothorax: a systematic review and meta-analysis. Dig Dis Sci 2016; 61 (11) 3321-3334
    CrossrefPubMedGoogle Scholar
  • 106 Huang PM, Kuo SW, Chen JS, Lee JM. Thoracoscopic mesh repair of diaphragmatic defects in hepatic hydrothorax: a 10-year experience. Ann Thorac Surg 2016; 101 (05) 1921-1927
    CrossrefPubMedGoogle Scholar
  • 107 Jung Y, Song SY, Na KJ, Chon SH, Jun CH, Choi SK. Minimally invasive surgical strategy for refractory hepatic hydrothorax. Eur J Cardiothorac Surg 2020; 57 (05) 881-887
    CrossrefPubMedGoogle Scholar
  • 108 Chen A, Massoni J, Jung D, Crippin J. Indwelling tunneled pleural catheters for the management of hepatic hydrothorax. A pilot study. Ann Am Thorac Soc 2016; 13 (06) 862-866
    CrossrefPubMedGoogle Scholar
  • 109 Kniese C, Diab K, Ghabril M, Bosslet G. Indwelling pleural catheters in hepatic hydrothorax: a single-center series of outcomes and complications. Chest 2019; 155 (02) 307-314
    CrossrefPubMedGoogle Scholar
  • 110 Shojaee S, Rahman N, Haas K. et al. Indwelling tunneled pleural catheters for refractory hepatic hydrothorax in patients with cirrhosis: a multicenter study. Chest 2019; 155 (03) 546-553
    CrossrefPubMedGoogle Scholar
  • 111 Carrion AF, Martin P. When to refer for liver transplantation. Am J Gastroenterol 2019; 114 (01) 7-10
    CrossrefPubMedGoogle Scholar
  • 112 Xiol X, Tremosa G, Castellote J. et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005; 18 (06) 672-675
    CrossrefPubMedGoogle Scholar
  • 113 Sersté T, Moreno C, Francoz C. et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol 2010; 22 (02) 207-212
    CrossrefPubMedGoogle Scholar